Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment by Goncalves, Sergio et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Neurology
Open Access Research article
Deferiprone targets aconitase: Implication for Friedreich's ataxia 
treatment
Sergio Goncalves, Vincent Paupe, Emmanuel P Dassa and Pierre Rustin*
Address: Inserm, U676, Hôpital Robert Debré, Paris, F-75019 France and Université Paris 7, Faculté de Médecine Denis Diderot, IFR02, Paris, 
France
Email: Sergio Goncalves - goncalves@rdebre.inserm.fr; Vincent Paupe - paupe@rdebre.inserm.fr; Emmanuel P Dassa - dassa@rdebre.inserm.fr; 
Pierre Rustin* - rustin@rdebre.inserm.fr
* Corresponding author    
Abstract
Background: Friedreich ataxia is a neurological disease originating from an iron-sulfur cluster
enzyme deficiency due to impaired iron handling in the mitochondrion, aconitase being particularly
affected. As a mean to counteract disease progression, it has been suggested to chelate free
mitochondrial iron. Recent years have witnessed a renewed interest in this strategy because of
availability of deferiprone, a chelator preferentially targeting mitochondrial iron.
Method:  Control and Friedreich's ataxia patient cultured skin fibroblasts, frataxin-depleted
neuroblastoma-derived cells (SK-N-AS) were studied for their response to iron chelation, with a
particular attention paid to iron-sensitive aconitase activity.
Results: We found that a direct consequence of chelating mitochondrial free iron in various cell
systems is a concentration and time dependent loss of aconitase activity. Impairing aconitase activity
was shown to precede decreased cell proliferation.
Conclusion: We conclude that, if chelating excessive mitochondrial iron may be beneficial at some
stage of the disease, great attention should be paid to not fully deplete mitochondrial iron store in
order to avoid undesirable consequences.
Background
Friedreich ataxia (FRDA) is a severe neurological disease
with progressive cerebellar ataxia associating cardiomyop-
athy. It originates from a triplet expansion in the first
intron of the gene coding for frataxin and the resulting
impaired transcription causes depletion of this mitochon-
drial protein [1]. The actual consensus states that frataxin
function, through the handling of mitochondrial iron, is
intimately related with the synthesis of iron-sulfur clusters
(ISC) subsequently distributed to the various cell com-
partments [2]. A number of ISC containing enzymes play
a crucial role in cell metabolism. In keeping with this, aco-
nitase was found severely affected in Friedreich ataxia and
its residual activity might be a crucial issue to determine
the course of the disease [3]. Indeed, while the activity of
the mitochondrial enzyme is determinant for the meta-
bolic flux through the tricarboxylic acid in the mitochon-
dria [4], the cytosolic counterpart of the aconitase is
known to tightly regulate the overall iron metabolism of
mammal cells [5]. Accordingly, loss of aconitase activity
has been previously shown to trigger cell death of cardiac
fibroblasts [6]. Beside the impaired ISC assembly, an
increased susceptibility to oxidative insult [7] and a late
mitochondrial iron accumulation [8] have been reported
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as a result of frataxin depletion. Therefore, both antioxi-
dant- and mitochondrial iron chelator-based therapies
have been initially considered [9]. However, while anti-
oxidants were readily trialled with some promising results
[10], iron-chelator therapy could not be initially assessed
because desferrioxamine, the only chelator in widespread
clinical use at that time, did not target mitochondrial iron
[11]. Recently the interest in using an iron chelation
approach was renewed due to the availability of
deferiprone, a chelator specifically targeting mitochon-
drial iron [12,13]. In this context, we studied the in vitro
effect of deferiprone in control and FRDA patient cultured
skin fibroblasts and in a shRNA frataxin-depleted neurob-
lastoma-derived cell line (SK-N-AS cells).
Methods
Fibroblasts derived from forearm biopsies taken with
informed consent from healthy controls and two FRDA
patients (10–20% residual frataxin mRNA in their fibrob-
lasts) were grown under standard conditions in Dul-
becco's modified Eagle's medium (DMEM; Gibco
Invitrogen, Cergy Pontoise, France) supplemented with
10% foetal calf serum, 10 mg/ml penicillin/streptomycin
and 2 mM L-Glutamine (as Glutamax™; Gibco Invitro-
gen). Final iron content in culture medium amounted to
2–3 μM. The medium (4 ml/25 cm2 flask; 3 ml/10 cm2
well) was changed each three days. Fibroblasts were
seeded at 18 × 103 cells/cm2. SK-N-AS cells, seeded at 150
× 103 cells/cm2, were grown in the same culture medium
added with 100 μM non essential amino acid mixture
(Gibco Invitrogen) and 200 μM uridine (Sigma-Aldrich,
St Quentin, Falavier, France). Fibroblasts were treated
with 25, 75 or 150 μM deferiprone for 7 days. SK-N-AS
cells were treated for a variable duration (0, 1, 7 days)
with 150 μM deferiprone final. The deferiprone effect on
these cells was in addition tested for 7 days using 10, 50,
150 μM of the drug. Cell counting was done after trypsi-
nation using the Quick Read Precision Cell (Globe Scien-
tific Inc., NJ, USA).
For the sake of comparison between cell types, SK-N-AS
cells derived from a neuroblastoma were also used after
frataxin silencing using shRNA. In brief, frataxin-depleted
SK-N-AS were obtained by transducing lentiviral particles
carrying a gene encoding for frataxin-directed shRNA and
a puromycin resistance cassette (MISSION™ TRC shRNA;
Sigma-Aldrich, St Louis, Missouri USA). Frataxin-targeting
sequence of the shRNA was
CCGGGCTGGACTCTTTAGCAGAGTTCTCGAGAACTCT-
GCTAAAGAGTCCAGCTTTTT. SK-N-AS cells were seeded
in 24-well plates. After 24 h, 2 μg/ml hexadimethrine bro-
mide was added just before infection with lentiviral parti-
cles. After 18 h, cells were washed 3 times with PBS.
Deferiprone targets aconitase enzyme Figure 1
Deferiprone targets aconitase enzyme. Aconitase inhibition triggered by deferiprone in (A) cultured skin fibroblasts from 
control (open square) and two Friedreich's ataxia patients after 7 d of culture. Time-dependent aconitase inhibition by 150 μM 
deferiprone in (B) control (open square) and frataxin-depleted (shRNA treated) SK-N-AS cells. Error bars correspond to 1 SE 
(n = 3); *** denotes p < 0.001; n.s. non significant. Experimental conditions as described under Methods.
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Successfully infected cells were selected with 10 μg/ml
puromycin (15 d).
Aconitase (EC 4.2.1.3) measurement was spectrophoto-
metrically carried out by following aconitate production
from citrate at 240 nm [3] on the supernatant (800 g × 5
min) of detergent-treated cells (0.2% lauryl maltoside).
All chemicals were of the purest grade available from
Sigma-Aldrich (St Quentin; Falavier, France). Protein con-
centration was measured according to Bradford method.
Data are shown as mean ± 1 SE. Measurements were ana-
lyzed by t test. All statistical tests were calculated using Sig-
maStat software (Sigma, St Louis, USA); p < 0.001 was
considered to indicate statistical significance and denoted
by *** for each value; n.s. non significant.
Results
Deferiprone gradually abolishes aconitase activity in 
human cultured cells
The activity of cytosolic and mitochondrial aconitase, two
ISC containing proteins, is known to be highly dependent
on iron availability [14]. We thus first investigated in
human cultured skin fibroblasts the capacity of the
enzymes to resist the iron depletion resulting from a
deferiprone treatment (Fig. 1A). Mitochondrial aconitase
activity represents up to 80% of the total aconitase activity
measurable in these cells. We observed that 150 μM
deferiprone treatments resulted in a significant and pro-
gressive loss of aconitase activity (up to 60% loss after 7
days) in control and patient's fibroblasts. An even more
pronounced loss of aconitase activity was induced by 150
μM deferiprone in frataxin-depleted and non-depleted
SK-N-AS cells (Fig. 1B). Deferiprone-induced loss of aco-
nitase activity was both dose- and time-dependent (Fig.
1). Noticeably, 150 μM deferiprone had no effect on the
activity of aconitase when added during enzyme assay
(not shown), indicative that the loss of aconitase activity
observed in cells should be ascribed to the chelation of
available iron rather than to a direct effect of the chelator
on the ISC of the enzyme.
Deferiprone inhibits growth of human cultured cells
We next investigated the consequences of the loss of aco-
nitase activity induced by 150 μM deferiprone (7 d) on
cell proliferation (Fig. 2). Not surprisingly in view of the
critical role of theses enzymes in cell metabolism [14], we
observed that the severe loss of aconitase activity was con-
comitant with a major impairment of cell growth of con-
trol and patient's fibroblasts (Fig. 2A, B) or of control and
frataxin-depleted SK-N-AS cells (Fig. 2C).
Discussion
The results reported in this study confirm that deferiprone
is a potent chelator of mitochondrial matrix iron [12]. As
such, it also potently impairs aconitase activity, presuma-
bly through reduced synthesis of the iron-sulfur cluster
machinery which makes use of available iron in the mito-
chondrial matrix with the help of frataxin [15]. Conflict-
ing results have been reported concerning mitochondrial
iron content of FRDA patient's fibroblasts which may or
not accumulate iron [16]. We show here that the abnor-
Deferiprone decreases cell proliferation Figure 2
Deferiprone decreases cell proliferation. Effect of 7 d-treatment with deferiprone (0–150 μM) on (A) control (open sym-
bol) and patient fibroblasts and on (C) control (open symbol) and frataxin-depleted SK-N-AS cells. A light microscope view (B) 
(×4) of control (a, b, c) and patient (d, e, f) fibroblasts, before treatment (18 h after seeding; a, d), or 7 d in the absence (b, e) 
or presence (c, f) of 150 μM deferiprone. Error bars correspond to 1 SE (n = 3); *** denotes p < 0.001; n.s. non significant. 
Experimental conditions as described under Methods.
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mal status of mitochondrial iron in Friedreich ataxia pos-
sibly at the origin of the hypersensitivity of these cells to
oxidative insults – associated or not with an increased
mitochondrial iron content – does not protect frataxin
depleted cells from the deleterious effect of iron chelation.
So far we have no idea of the concentration of deferiprone
which might be reached in brain tissues of treated
patients. Nevertheless, a mean peak plasma concentration
of deferiprone has been estimated to be about 150–200
μM when deferiprone is provided in one daily dose of 25
mg/kg of body weight [17]; a value similar to the 150 μM
of deferiprone used in this in vitro study. A lower concen-
tration is probably maintained in tissues, however if
deferiprone concentration is efficient to empty mitochon-
drial iron it should also gradually impair aconitase activity
in the mitochondrial matrix. Obviously, the activity of
additional iron-requiring enzymes might be affected as
well due to excessive lowering of mitochondrial iron, e.g.
the mitochondrial ribonucleotide reductase [18]. Assay-
ing the iron-sensitive activity of these mitochondrial
enzymes might provide useful maker(s) for iron chelator
toxicity in future clinical studies.
Conclusion
Consequently, while iron chelation might help the mito-
chondrion to cope with excessive iron at some particular
step of the disease, i.e. when iron accumulation is instru-
mental, its putative efficacy on a long term will predicta-
bly be associated with a detrimental mitochondrial iron
deprivation. Ultimately, this might further impair the
mitochondrial synthesis of ISC, already a critical issue in
Friedreich ataxia.
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